Trial Profile

A non-interventional study evaluating CTI-1601 in healthy volunteers

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomlabofusp (Primary)
Indications Friedreich's ataxia
Focus Therapeutic Use
Sponsors Larimar Therapeutics

Most Recent Events

29 Mar 2022 New trial record
25 Mar 2022 According to a Larimar Therapeutics media release, Enrollment in this study was completed in early 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com